What is William Blair’s Estimate for KZR Q1 Earnings?

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for Kezar Life Sciences in a report released on Tuesday, March 25th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($2.95) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($4.39) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2026 earnings at ($3.03) EPS, Q3 2026 earnings at ($3.10) EPS and Q4 2026 earnings at ($3.16) EPS.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($2.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06).

Several other brokerages have also recently weighed in on KZR. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd. Wells Fargo & Company dropped their price target on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Thursday, December 19th.

Kezar Life Sciences Trading Down 4.1 %

Shares of KZR stock opened at $4.92 on Friday. The stock has a market cap of $35.90 million, a P/E ratio of -0.37 and a beta of 0.49. Kezar Life Sciences has a 1 year low of $4.90 and a 1 year high of $9.27. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $6.00 and a 200 day simple moving average of $6.68.

Institutional Investors Weigh In On Kezar Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in KZR. Ikarian Capital LLC lifted its position in shares of Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares during the last quarter. XTX Topco Ltd raised its stake in Kezar Life Sciences by 256.1% during the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after acquiring an additional 37,504 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after acquiring an additional 81,678 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Kezar Life Sciences in the 4th quarter valued at approximately $833,000. Finally, BML Capital Management LLC bought a new stake in shares of Kezar Life Sciences during the 4th quarter valued at approximately $327,000. 67.90% of the stock is currently owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.